2011
Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells
Zhao X, Ogunwobi O, Liu C. Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells. PLOS ONE 2011, 6: e21980. PMID: 21829603, PMCID: PMC3148218, DOI: 10.1371/journal.pone.0021980.Peer-Reviewed Original ResearchConceptsBcl-2 inhibitorsCombination treatmentHCC cellsABT-263Survivin inhibitionHepatocellular carcinomaHuman liver cancer tissuesSingle treatmentFuture clinical trialsApoptotic effectsLiver cancer tissuesLiver cancer therapyERK activationHCC cell linesHepatocellular carcinoma cellsPreclinical dataClinical trialsTherapeutic effectLow doseNormal human hepatocytesCancer tissuesYM-155High dosesNovel Bcl-2 inhibitorABT-263-induced apoptosis
2006
An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens
Wang B, He J, Liu C, Chang L. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24: 3477-3489. PMID: 16530303, PMCID: PMC1850619, DOI: 10.1016/j.vaccine.2006.02.025.Peer-Reviewed Original ResearchConceptsTumor-associated antigensDendritic cellsModification of DCsMultiple tumor-associated antigensStrong anti-tumor responsesReactive dendritic cellsAnti-tumor responseT cell responsesLentiviral vectorsCancer-specific antigensCell antigen 2Tumor-bearing miceThymidine kinase suicide geneDC vaccinesVaccine modalitiesCancer immunotherapyCancer patientsTherapeutic injectionsTherapeutic effectExtended survivalAntigen 2Danger signalsVivo eliminationCell responsesTherapeutic potential